학술논문
Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis
Document Type
Article
Author
Source
In Gynecologic Oncology September 2022 166(3):582-588
Subject
Language
ISSN
0090-8258